SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Aljabery Firas) "

Search: WFRF:(Aljabery Firas)

  • Result 31-40 of 61
Sort/group result
   
EnumerationReferenceCoverFind
31.
  • Jahnson, Staffan, et al. (author)
  • Modulation of the inflammatory response after sclerotherapy for hydrocoele/spermatocoele
  • 2019
  • In: BJU International. - : Wiley-Blackwell Publishing Inc.. - 1464-4096 .- 1464-410X. ; 123:5A, s. E63-E68
  • Journal article (peer-reviewed)abstract
    • ObjectiveTo investigate the modulation of the inflammatory response after sclerotherapy for hydrocoele/spermatocoele.Patients and MethodsAll patients with hydrocoele or spermatocoele presenting at the Department of Urology, University Hospital, Linköping, Sweden, from 2006 to 2012, were included in this prospective observational study of sclerotherapy for hydrocoele/spermatocoele using polidocanol as a sclerosing agent and adjuvant antibiotic and anti‐inflammatory medication (AAAM) for modulation of the inflammatory response. Patients were clinically evaluated within 24–48 h after a complication or adverse event possibly related to sclerotherapy. Evaluation of cure was scheduled after 3 months and re‐treatment, if necessary was carried out in the same manner as the first treatment. Groups of patients were compared using the chi‐squared test and logistic regression analysis.ResultsFrom a total of 191 patients, AAAM was given to 126, of whom 5% had subclinical epididymitis/swelling (SES) compared to 26% of the patients without AAAM (P < 0.001). No other complication was observed. The rate of cure for the whole group of patients was 93% after one or two treatments and significantly higher in the group with AAAM than in the group without AAAM (96% vs 88%, P = 0.03).ConclusionsModulation of the inflammatory response after sclerotherapy resulted in a lower incidence of SES and an increased cure rate.
  •  
32.
  • Jahnson, Staffan, et al. (author)
  • Telomerase reverse transcriptase mutation and the p53 pathway in T1 urinary bladder cancer
  • 2022
  • In: BJU International. - : WILEY. - 1464-4096 .- 1464-410X. ; 129:5, s. 601-609
  • Journal article (peer-reviewed)abstract
    • Objective To study the telomerase reverse transcriptase (TERT) mutation and the p53 pathway in T1 urinary bladder cancer (UBC). Materials and Methods This prospectively performed population-based study included all patients in the Southeast Healthcare Region in Sweden with T1 UBC registered in the period 1992-2001, inclusive. Given that p53 and TERT are important factors for tumour proliferation, although their interrelationships are unknown, we assessed both the TERT and the p53 mutations. Furthermore, we conducted a p53 immunohistochemistry (IHC) analysis using two thresholds for p53 positivity: 10% of tumour cells and 50% of tumour cells (p53 IHC50%). Cox proportional hazards analysis and Kaplan-Meier curves were used to study time to tumour progression. Results Out of 158 patients, we observed the TERT mutation in 74 (47%), the p53 mutation in 48 (30%), and p53 IHC50% positivity in 72 patients (46%). The TERT mutation was more common in p53 mutation-positive patients (P = 0.009), and the latter group also had more patients with p53 IHC50%-positive tumour cells (P = 0.02). In the TERT mutation-negative tumours a p53-positive mutation was associated with a shorter time to progression (P = 0.03) compared to patients with p53-negative mutation. In contrast, in tumours with both TERT mutation positivity and p53 mutation positivity, a longer time to progression was observed in the group with p53 IHC50% positivity compared to the group with p53 IHC50%-negative tumours. Conclusions In stage T1 UBC, the combination of the TERT mutation and the p53 mutation was associated with tumour progression. A protective effect of the TERT promotor mutation against tumour progression induced by the p53 mutation and subsequent p53 accumulation in tumour cells might be possible, but further investigations are necessary.
  •  
33.
  • Jahnson, Staffan, et al. (author)
  • Thromboembolism in Muscle-Invasive Bladder Cancer : A Population-based Nationwide Study
  • 2021
  • In: Bladder Cancer. - : IOS Press. - 2352-3727 .- 2352-3735. ; 7:2, s. 161-171
  • Journal article (peer-reviewed)abstract
    • BACKGROUND: Routine VTE prophylaxis within 30 days of radical cystectomy (RC) for urinary bladder cancer (UBC) is used to protect from venous thromboembolism (VTE). However, randomized studies and nationwide population-based studies are lacking.OBJECTIVE: To study VTE and risk factors for VTE in muscle-invasive UBC in a nationwide population-based series, with a focus on the association with RC with and without chemotherapy.MATERIALS AND METHODS: We studied all patients with clinical stage T2-T4 UBC diagnosed 1997 to 2014 in the Bladder Cancer Data Base Sweden (BladderBaSe). Previous VTE events and risk factors for VTE were registered from 1987. Cox regression analyses and Kaplan-Meier curves were performed to study risk factors for VTE and cumulative incidence of VTE.RESULTS: In 9720 patients (71% males) with a median age of 74 years 546 (5.6%) had VTE after diagnosis. In Cox analyses controlling for patient's and tumour characteristics, and risk factors for VTE, VTE after diagnosis and first treatment date were associated with chemotherapy with or without RC. Cumulative incidence of VTE increased during 24 months after diagnosis and first treatment date. VTE were less common in patients with previous cardiovascular disease.CONCLUSION: VTE was commonly observed after 30 days from diagnosis and from first treatment date in patients with T2-T4 UBC, particularly after chemotherapy. The findings suggest that long-term intervention studies of benefit and possible harms of VTE prophylaxis after UBC should be undertaken.
  •  
34.
  • Jancke, Georg, et al. (author)
  • Intravesical instillations and cancer-specific survival in patients with primary carcinoma in situ of the urinary bladder
  • 2017
  • In: Scandinavian journal of urology. - : Taylor & Francis. - 2168-1805 .- 2168-1813. ; 51:2, s. 124-129
  • Journal article (peer-reviewed)abstract
    • OBJECTIVE: The aim of this study was to evaluate the use of intravesical treatment and cancer-specific survival of patients with primary carcinoma in situ (CIS).MATERIALS AND METHODS: Data acquisition was based on the Swedish National Registry of Urinary Bladder Cancer by selecting all patients with primary CIS. The analysis covered gender, age, hospital type and hospital volume. Intravesical treatment and death due to bladder cancer were evaluated by multivariate logistic regression and multivariate Cox analysis, respectively.RESULTS: The study included 1041 patients (median age at diagnosis 72 years) with a median follow-up of 65 months. Intravesical instillation therapy was given to 745 patients (72%), and 138 (13%) died from bladder cancer during the observation period. Male gender [odds ratio (OR) = 1.56, 95% confidence interval (CI) 1.13-2.17] and treatment at county (OR = 1.65, 95% CI 1.17-2.33), university (OR =2.12, 95% CI 1.48-3.03) or high-volume (OR = 1.92, 95% CI 1.34-2.75) hospitals were significantly associated with higher odds of intravesical instillations. The age category ≥80 years had a significantly lower chance of receiving intravesical therapy (OR = 0.44, 95% CI 0.26-0.74) and a significantly higher risk of dying from bladder cancer (hazard ratio = 3.03, 95% CI 1.71-5.35).CONCLUSION: Significantly more frequent use of intravesical treatment of primary CIS was found for males and for patients treated at county, university and high-volume hospitals. Age ≥80 years was significantly related to less intravesical treatment and poorer cancer-specific survival.
  •  
35.
  •  
36.
  •  
37.
  •  
38.
  • Jerlström, Tomas, 1969-, et al. (author)
  • No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy : a nation-wide register-based study
  • 2020
  • In: World journal of urology. - : Springer. - 0724-4983 .- 1433-8726. ; 38:2, s. 381-388
  • Journal article (peer-reviewed)abstract
    • PURPOSE: Preoperative chemotherapy is underused in conjunction with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) due to concerns for complications and delay of surgery. Prospective data on short-term complications from population-based settings with frequent use of preoperative chemotherapy and standardised reporting of complications is lacking.METHODS: We identified 1,340 patients who underwent RC between 2011 and 2015 in Sweden due to MIBC according to the Swedish Cystectomy Register. These individuals were followed through linkages to several national registers. Propensity score adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for complications and death within 90 days of surgery, comparing patients receiving preoperative chemotherapy or not.RESULTS: Minimum two cycles of preoperative chemotherapy were given to 519 (39%) of the patients, who on average tended to be younger, have higher education, better physical status, and more advanced bladder cancer than patients not receiving chemotherapy. After adjusting for these and other parameters, there was no association between treatment with preoperative chemotherapy and short-term complications (OR 1.06 95% CI 0.82-1.39) or mortality (OR 0.75 95% CI 0.36-1.55). We observed a risk reduction for gastrointestinal complications among patients who received preoperative chemotherapy compared with those who did not (OR 0.49 95% CI 0.30-0.81).CONCLUSION: This nation-wide population-based observational study does not suggest that preoperative chemotherapy, in a setting with high utilisation of such treatment, is associated with an increased risk of short-term complications in MIBC patients treated with radical cystectomy.
  •  
39.
  •  
40.
  • Krantz, David, et al. (author)
  • Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer
  • 2018
  • In: European Urology. - : Elsevier. - 0302-2838 .- 1873-7560. ; 74:6, s. 688-692
  • Journal article (peer-reviewed)abstract
    • Evidence indicates that neoadjuvant chemotherapy (NAC) may promote antitumour immune responses by activating T cells. The tumour-draining sentinel node (SN) is a key site to study tumour-specific T cell activation, being the primary immunological barrier against the tumour. In this prospective study, we set out to elucidate the effects of NAC on T cell subsets in the SNs of patients with muscle-invasive urothelial bladder cancer. We found that CD8+ effector T (Teff) cell exhaustion was reduced after NAC treatment, while cytotoxicity was increased. Additionally, in complete responders (CR patients), these cells were functionally committed effectors, as displayed by epigenetic analysis. In CD4+ Teffs, NAC treatment was associated with increased clonal expansion of tumour-specific SN-derived cells, as demonstrated by a specific cell reactivity assay. In contrast, we observed an attenuating effect of NAC on regulatory T cells (Tregs) with a dose-dependent decrease in Treg frequency and reduced effector molecule expression in the remaining Tregs. In addition, multicolour flow cytometry analysis revealed that CR patients had higher Teff to activated Treg ratio, promoting antitumoural T cell activation. These results suggest that NAC reinforces the antitumour immune response by activating the effector arm of the T cell compartment and diminishing the influence of suppressive Tregs.PATIENT SUMMARY: In this report, we analysed the effect of chemotherapy on immune cell subsets of 40 patients with advanced bladder cancer. We found that chemotherapy has a positive effect on immune effector T cells, whereas an opposite, diminishing effect was observed for immune-suppressive regulatory T cells. We conclude that chemotherapy reinforces the antitumour immune response in bladder cancer patients.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 31-40 of 61
Type of publication
journal article (58)
other publication (1)
doctoral thesis (1)
research review (1)
Type of content
peer-reviewed (56)
other academic/artistic (5)
Author/Editor
Aljabery, Firas (40)
Sherif, Amir (37)
Liedberg, Fredrik (32)
Ströck, Viveka (32)
Jahnson, Staffan (30)
Jerlström, Tomas, 19 ... (24)
show more...
Abdul-Sattar Aljaber ... (19)
Häggström, Christel (19)
Malmström, Per-Uno (19)
Holmberg, Lars (19)
Hagberg, Oskar (19)
Gårdmark, Truls (15)
Söderkvist, Karin (12)
Hosseini, Abolfazl (11)
Gardmark, T. (11)
Huge, Ylva (11)
Johansson, Markus (10)
Alamdari, Farhood (8)
Ullen, A (8)
Hosseini, A. (7)
Ullén, Anders (7)
Olsson, Hans (6)
Svensson, Johan, 197 ... (6)
Jancke, Georg (5)
Winqvist, Ola (4)
Holmström, Benny (4)
Shabo, Ivan (4)
Holmbom, Martin (4)
Styrke, Johan (4)
Pelander, Sofia (4)
Bobjer, Johannes (4)
Kjölhede, Henrik, 19 ... (3)
Jahnson, Staffan, 19 ... (3)
Garmo, Hans (3)
Zirakzadeh, A. Ali (3)
Rosell, Johan (3)
Eriksson, Victoria (3)
Riklund, Katrine (2)
Gudjonsson, Sigurdur (2)
Abuhasanein, Suleima ... (2)
Söderström, Karin (2)
Hartana, Ciputra Adi ... (2)
Winerdal, Malin E. (2)
Krantz, David (2)
Palmqvist, Karin (2)
Gimm, Oliver (2)
Saudi, Aus (2)
Jakubczyk, Tomasz (2)
Fall, Katja, 1971- (2)
Ochoa-Figueroa, Migu ... (2)
show less...
University
Linköping University (56)
Umeå University (40)
Karolinska Institutet (38)
Lund University (28)
Uppsala University (27)
Örebro University (24)
show more...
University of Gothenburg (22)
Malmö University (1)
show less...
Language
English (61)
Research subject (UKÄ/SCB)
Medical and Health Sciences (61)
Natural sciences (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view